227 related articles for article (PubMed ID: 10466673)
1. Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia.
Sumino H; Ichikawa S; Kanda T; Nakamura T; Sakamaki T
Lancet; 1999 Aug; 354(9179):650. PubMed ID: 10466673
[TBL] [Abstract][Full Text] [Related]
2. Hormone replacement therapy and serum uric acid.
Ovalle F; Bell DS
Lancet; 1999 Nov; 354(9190):1643; author reply 1644. PubMed ID: 10560697
[No Abstract] [Full Text] [Related]
3. Hormone replacement therapy and serum uric acid.
Kashyap AS; Kashyap S
Lancet; 1999 Nov; 354(9190):1643-4. PubMed ID: 10560698
[No Abstract] [Full Text] [Related]
4. Menopause, postmenopausal hormone use and serum uric acid levels in US women--the Third National Health and Nutrition Examination Survey.
Hak AE; Choi HK
Arthritis Res Ther; 2008; 10(5):R116. PubMed ID: 18822120
[TBL] [Abstract][Full Text] [Related]
5. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: the Heart and Estrogen-Progestin Replacement Study (HERS).
Simon JA; Lin F; Vittinghoff E; Bittner V;
Ann Epidemiol; 2006 Feb; 16(2):138-45. PubMed ID: 16039873
[TBL] [Abstract][Full Text] [Related]
6. Serum uric acid levels and hormone therapy type: a retrospective cohort study of postmenopausal women.
Jung JH; Song GG; Lee YH; Kim JH; Hyun MH; Choi SJ
Menopause; 2018 Jan; 25(1):77-81. PubMed ID: 28796699
[TBL] [Abstract][Full Text] [Related]
7. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy.
Kim CJ; Min YK; Ryu WS; Kwak JW; Ryoo UH
Arch Intern Med; 1996 Aug 12-26; 156(15):1693-700. PubMed ID: 8694668
[TBL] [Abstract][Full Text] [Related]
8. Short-term results of transdermal estrogen replacement therapy in cardiovascular disease-free postmenopausal females with and without hypertension.
Modena MG; Rossi R; Muia N; Origliani G; Rombolà O; Molinari R
G Ital Cardiol; 1998 Jun; 28(6):636-44. PubMed ID: 9672776
[TBL] [Abstract][Full Text] [Related]
9. [Hormone replacement therapy and cardiovascular risk in postmenopausal women].
Kovacev-Zavisić B; Icin T; Kovacev N
Med Pregl; 2009; 62 Suppl 3():85-90. PubMed ID: 19702123
[TBL] [Abstract][Full Text] [Related]
10. [Biological and practical aspects of hormone replacement therapy: an approach to cardiovascular disease prevention in postmenopausal women].
da Silva PM
Rev Port Cardiol; 1999 Nov; 18(11):1047-55. PubMed ID: 10608165
[TBL] [Abstract][Full Text] [Related]
11. [Influence of estrogen replacement therapy on atherogenic profile in postmenopausal women].
Alfonso Cano C; Vez García MD; García Urruticoechea P; Tornel Osorio PL; Canteras Jordana M; Abellán Alemán J
An Med Interna; 2003 Feb; 20(2):70-4. PubMed ID: 12703158
[TBL] [Abstract][Full Text] [Related]
12. [Hormone replacement therapy in postmenopausal women and cardiovascular risk].
Karam C; Bourmayan C; Desnos M; Guérot C
Ann Cardiol Angeiol (Paris); 1995 Apr; 44(4):195-201. PubMed ID: 7632028
[TBL] [Abstract][Full Text] [Related]
13. The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor-alpha and hepatocyte growth factor in postmenopausal women.
Sezer Ozer K; Erenus M; Yoldemir T
Climacteric; 2009 Feb; 12(1):66-71. PubMed ID: 19012050
[TBL] [Abstract][Full Text] [Related]
14. Relationships between serum uric acid, adiponectin and arterial stiffness in postmenopausal women.
Park JS; Kang S; Ahn CW; Cha BS; Kim KR; Lee HC
Maturitas; 2012 Dec; 73(4):344-8. PubMed ID: 23127592
[TBL] [Abstract][Full Text] [Related]
15. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators.
Nabulsi AA; Folsom AR; White A; Patsch W; Heiss G; Wu KK; Szklo M
N Engl J Med; 1993 Apr; 328(15):1069-75. PubMed ID: 8384316
[TBL] [Abstract][Full Text] [Related]
16. Questioning the cardioprotective action of hormone replacement therapy in postmenopausal women.
Mascitelli L; Goldstein MR; Pezzetta F
J Cardiovasc Med (Hagerstown); 2009 Aug; 10(8):657-8. PubMed ID: 19424079
[TBL] [Abstract][Full Text] [Related]
17. Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease.
Yeboah J; Klein K; Brosnihan B; Reboussin D; Herrington DM
Menopause; 2008; 15(6):1060-4. PubMed ID: 18521047
[TBL] [Abstract][Full Text] [Related]
18. Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women.
Maffei S; Del Ry S; Prontera C; Clerico A
Clin Sci (Lond); 2001 Nov; 101(5):447-53. PubMed ID: 11672449
[TBL] [Abstract][Full Text] [Related]
19. Is physical activity as effective in reducing risk of cardiovascular disease as estrogen replacement therapy in postmenopausal women?
Wong S; Wong J
Int J Nurs Stud; 1999 Oct; 36(5):405-14. PubMed ID: 10519685
[TBL] [Abstract][Full Text] [Related]
20. [Postmenopausal hormone replacement and cardiovascular disease].
Oian P; Aune B
Tidsskr Nor Laegeforen; 1993 Jan; 113(2):193-6. PubMed ID: 8430399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
